Active low molecular weight variants of angiotensin converting enzyme 2 (ace2)
AssigneeNorthwestern University
InventorsDaniel Batlle, Jan Wysocki
Life of this patent
Estimating the term…
Loading patent…
AssigneeNorthwestern University
InventorsDaniel Batlle, Jan Wysocki
Estimating the term…
Disclosed are variants of ACE2, pharmaceutical compositions comprising the variants of ACE2, and treatment methods for reducing Angiotensin II (1-8) plasma levels and/or increasing Angiotensin (1-7) plasma levels in a subject in need thereof. The disclosed variants of ACE2 may include polypeptide fragments of ACE2 having ACE2 activity for converting AngII(1-8) to Ang(1-7). Suitable subjects suitable for the disclosed methods of treatment may include subjects having or at risk for developing diabetic and non-diabetic chronic kidney disease, acute renal failure and its prevention, chronic kidney disease, severe hypertension, scleroderma and its skin, pulmonary, kidney and hypertensive complications, malignant hypertension, renovascular hypertension secondary to renal artery stenosis, idiopathic pulmonary fibrosis, liver fibrosis such as in liver cirrhosis patients, an aortic aneurysm, cardiac fibrosis and remodeling, left ventricular hypertrophy, and an acute stroke.
-19. (canceled)
A method of delivering ACE2 activity to the kidney, the method comprising administering to a subject suffering from or at risk of developing kidney damage a pharmaceutical composition that delivers into the kidney an enzymatically active ACE2 variant that is sufficiently C-terminally truncated that it is susceptible to glomerular filtration.
An active human angiotensin converting enzyme 2 (ACE2) variant that is C-terminally truncated relative to SEQ ID NO:1 at its residue analogous to residue 619 in mouse ACE2 of SEQ ID NO:2.
A fusion protein comprising:
A conjugate comprising an angiotensin converting enzyme 2 (ACE2) variant that is C-terminally truncated relative to a reference mouse homolog (SEQ ID NO:2) at a site after its residue corresponding to residue 522 of SEQ ID NO:2, so that the ACE2 variant shows ACE2 enzymatic activity, the ACE2 variant being sufficiently truncated that it is amenable to glomerular filtration and showing ACE2 enzymatic activity conjugated to a polyethylene glycol polymer.
A conjugate comprising an angiotensin converting enzyme 2 (ACE2) variant that is C-terminally truncated relative to a reference mouse homolog (SEQ ID NO:2) at a site after its residue corresponding to residue 522 of SEQ ID NO:2, so that the ACE2 variant shows ACE2 enzymatic activity, the ACE2 variant being sufficiently truncated that it is amenable to glomerular filtration and showing ACE2 enzymatic activity conjugated to a nanoparticle.
A pharmaceutical composition that comprises or delivers:
Dependencies are inferred from the claim text.